Premium
Synthesis, characterization and biodistribution of 99m Tc(CO) 3 –ABP and comparison with 99m Tc–ABP
Author(s) -
Liu Jian,
Wang Fenglong,
Zhang Junbo,
Yang Shuye,
Guo Haixun,
Wang Xuebin
Publication year - 2007
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.1455
Subject(s) - chemistry , biodistribution , radiochemistry , partition coefficient , ligand (biochemistry) , high performance liquid chromatography , decomposition , technetium , technetium 99m , nuclear chemistry , chromatography , nuclear medicine , receptor , in vitro , scintigraphy , biochemistry , organic chemistry , medicine
The (l‐hydroxy‐4‐amino‐butylidene‐l,l‐bisphosphate) (ABP) is a compound that inhibits bone resorption, and a highly effective drug in the treatment of metastatic bone disease. The fac‐[ 99m Tc(CO) 3 (H 2 O) 3 ] + precursor was reacted with ABP in saline (pH=3–4) at 45°C for 15 min to produce the 99m Tc(CO) 3 –ABP complex. The radiochemical purity (RCP) of the product was over 90% as measured by thin layer chromatography and high‐performance liquid chromatography. No decomposition of the complex at room temperature (25°C) was observed over a period of 6 h. Its partition coefficient indicated that it was a weak hydrophilic complex. The biodistribution in normal mice of 99m Tc(CO) 3 –ABP complex differed greatly from that of 99m Tc–ABP, and the former had a lower bone uptake as compared with that of the latter. The experiment results showed that the incorporation of the [ 99m Tc(CO) 3 ] + core into the ABP ligand may drastically change the characterization and biological features as compared with 99m Tc–ABP. Copyright © 2007 John Wiley & Sons, Ltd.